Please assess the completion status of the following clinical trial:

Trial Title: Sertraline Effect in Uremic Pruritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥1 month of maintenance haemodialysis, 3 times per week for 4 hours.~2. Adult patients with ages between 18-80 years.~Exclusion Criteria:~1. Primary skin diseases (eczema, psoriasis, allergic dermatitis or drug rash).~2. Peripheral neuropathy, thyroid disease, leukemia, lymphoma, liver disease, Systemic lupus erythematosus or pregnancy.~3. Patients who consumed emollients cream, antihistamine, opioid antagonist, immunosuppressants, cholestyramine, corticosteroids or UVB phototherapy 1 month before study.~4. calcium X phosphorus (Ca X P) \>55.0 mg/dl, P \>5.5 mg/dl, parathyroid hormone (PTH) \>450 pg/ml.~5. Selective serotonin reuptake inhibitors intolerance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- sertraline (Type: EXPERIMENTAL): they will receive sertraline at the intended dose of 50 mg twice daily for 8 weeks.
- placebo (Type: PLACEBO_COMPARATOR): They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).